• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    PACS Group Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    11/26/24 4:33:35 PM ET
    $PACS
    Hospital/Nursing Management
    Health Care
    Get the next $PACS alert in real time by email
    pacs-20241120
    false000200118400020011842024-11-202024-11-20

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): November 20, 2024
    PACS GROUP, INC.
    (Exact name of registrant as specified in its charter)
    Delaware001-4201192-3144268
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification Number)
    262 N. University Ave.
    Farmington, Utah 84025
    (Address of principal executive offices, including Zip Code)
    Registrant’s telephone number, including area code: (801) 447-9829
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading
    Symbol(s)
    Name of each exchange
    on which registered
    Common Stock, $0.001 par value per sharePACSThe New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
    On November 20, 2024, PACS Group, Inc., a Delaware corporation (the “Company”), received a notice of noncompliance (the “NYSE Notice”) from the New York Stock Exchange (“NYSE”) noting that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual, Annual and Quarterly Report Timely Filing Criteria due to the delayed filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q”).
    The NYSE has informed the Company that it has up to six months from November 19, 2024 to file its Form 10-Q to regain compliance. The Company intends to file the Form 10-Q and regain compliance within this initial six month period, however, there can be no assurance that the Company will ultimately regain compliance with all applicable NYSE listing standards.
    Item 7.01 Regulation FD Disclosure.
    On November 26, 2024, the Company issued a press release announcing its receipt of the NYSE Notice. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
    The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibit hereto, is material or that the dissemination of such information is required by Regulation FD.
    Cautionary Statement Regarding Forward-Looking Statements
    This Current Report on Form 8-K contains “forward-looking statements.” These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements often use words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “outlook,” “forecast,” “target,” “trend,” “plan,” “goal,” or other words of comparable meaning or future-tense or conditional verbs such as “may,” “will,” “should,” “would,” or “could.” Statements concerning the Company’s future are forward-looking statements, and are based on management’s current expectations, assumptions and beliefs about the Company’s business, financial performance, operating results, the industry in which the Company operates and possible future events. These statements include, but are not limited to, statements regarding the Company’s expectations regarding the timing of the ongoing investigation and the timing of and its ability to make the Company’s Form 10-Q filing. Forward-looking statements convey the Company’s expectations, intentions, or forecasts about future events, circumstances, results, or aspirations. Forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions, which may change over time and many of which are beyond the Company’s control, and that could cause the Company’s actual results to materially and adversely differ from those expressed in any forward-looking statement, including the outcome of any ongoing government or internal investigations, risks associated with litigation, and the other risks described in the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2024 and other filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this Current Report on Form 8-K, and the Company does not undertake an obligation to update these forward-looking statements after such date.
    Item 9.01 Financial Statements and Exhibits.
    Exhibit No.Description
    99.1
    Press Release dated November 26, 2024
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    PACS GROUP, INC.
    Date: November 26, 2024
    By:/s/ Derick Apt
    Derick Apt
    Chief Financial Officer

    Get the next $PACS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PACS

    DatePrice TargetRatingAnalyst
    12/17/2024$18.00Overweight → Neutral
    Analyst
    11/6/2024$40.00Overweight
    JP Morgan
    10/9/2024$50.00Buy
    UBS
    9/11/2024$45.00Buy
    Citigroup
    6/28/2024$35.00Outperform
    Macquarie
    More analyst ratings

    $PACS
    SEC Filings

    See more
    • PACS Group Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

      8-K - PACS Group, Inc. (0002001184) (Filer)

      6/16/25 4:03:15 PM ET
      $PACS
      Hospital/Nursing Management
      Health Care
    • PACS Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events

      8-K - PACS Group, Inc. (0002001184) (Filer)

      6/2/25 4:10:32 PM ET
      $PACS
      Hospital/Nursing Management
      Health Care
    • SEC Form NT 10-Q filed by PACS Group Inc.

      NT 10-Q - PACS Group, Inc. (0002001184) (Filer)

      5/16/25 4:10:12 PM ET
      $PACS
      Hospital/Nursing Management
      Health Care

    $PACS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PACS Group downgraded by Analyst with a new price target

      Analyst downgraded PACS Group from Overweight to Neutral and set a new price target of $18.00

      12/17/24 8:16:05 AM ET
      $PACS
      Hospital/Nursing Management
      Health Care
    • JP Morgan resumed coverage on PACS Group with a new price target

      JP Morgan resumed coverage of PACS Group with a rating of Overweight and set a new price target of $40.00

      11/6/24 6:27:46 AM ET
      $PACS
      Hospital/Nursing Management
      Health Care
    • UBS initiated coverage on PACS Group with a new price target

      UBS initiated coverage of PACS Group with a rating of Buy and set a new price target of $50.00

      10/9/24 7:56:46 AM ET
      $PACS
      Hospital/Nursing Management
      Health Care

    $PACS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Lewis Michelle Renee covered exercise/tax liability with 16,777 shares, decreasing direct ownership by 5% to 326,591 units (SEC Form 4)

      4 - PACS Group, Inc. (0002001184) (Issuer)

      4/16/25 7:32:30 PM ET
      $PACS
      Hospital/Nursing Management
      Health Care
    • Chief Compliance Officer Lee Joseph Robert covered exercise/tax liability with 28,763 shares, decreasing direct ownership by 4% to 648,122 units (SEC Form 4)

      4 - PACS Group, Inc. (0002001184) (Issuer)

      4/16/25 7:31:48 PM ET
      $PACS
      Hospital/Nursing Management
      Health Care
    • Officer Sanford Peter covered exercise/tax liability with 72,924 shares, decreasing direct ownership by 5% to 1,280,872 units (SEC Form 4)

      4 - PACS Group, Inc. (0002001184) (Issuer)

      4/16/25 7:31:05 PM ET
      $PACS
      Hospital/Nursing Management
      Health Care